JPS5849310A - Preparation of useful glycyrrhizin solution - Google Patents
Preparation of useful glycyrrhizin solutionInfo
- Publication number
- JPS5849310A JPS5849310A JP14660281A JP14660281A JPS5849310A JP S5849310 A JPS5849310 A JP S5849310A JP 14660281 A JP14660281 A JP 14660281A JP 14660281 A JP14660281 A JP 14660281A JP S5849310 A JPS5849310 A JP S5849310A
- Authority
- JP
- Japan
- Prior art keywords
- glycyrrhizin
- solution
- salt
- water
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims description 53
- 239000004378 Glycyrrhizin Substances 0.000 title claims description 52
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title claims description 52
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title claims description 51
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title claims description 51
- 235000019410 glycyrrhizin Nutrition 0.000 title claims description 51
- 239000000243 solution Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000004202 carbamide Substances 0.000 description 15
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 239000003513 alkali Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000004299 sodium benzoate Substances 0.000 description 5
- 235000010234 sodium benzoate Nutrition 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001062872 Cleyera japonica Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- -1 glycyrrhetinth Chemical compound 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
本角−は富mにおいて、4I用なりリチルリチン#IW
L′41ニー纏する方法に関する−のである。
せ卑有効成分クリチルリチンは優れたる抗炎症作用を有
し、従来抗アレル中−剤“としHonkaku is for 4I in rich m, lycyrrhizin #IW
L'41 - This is about how to wear your knees. The active ingredient crityrrhizin has excellent anti-inflammatory effects and has been used as an anti-allergic agent.
【重賛視されてきた。近
時慢性肝炎疾患の肝機能改善に顕著な薬効を奏すること
が内外で実証され、又r−インターフェロンの1#起剤
としてfE−されて−る。従って今日益々その安定なる
グリチルリチン真剤の量粛が要望されている。
ζ−に簡単にグリチルリチン及びその塩の階状について
述べる。グリチルリチン(グリチルリチン#l)はグリ
チルレチン績のジグルクロンaI!−会体で、三塩基酸
である1、これは希エタノールに1緩、エーテルに小書
、高融点で、水には鶏時でも礁めてJll鋳性のもので
ある。グリチルリチンのモノ塩はグリチルレチント同様
に綬性を呈し、水中ではその表面が寒天状を呈し、常温
では水Klけ―い◎^温では溶解するが、1ml低下と
共にモノ塩がゲル状に析出する。しかしジ及びトリaK
なると水KQT−114性になる。
グリチルリデン#i酸分解でグリチルレチン酸とグルク
ロン敵に分解し、アルカリと加温すると黄変する。
コノ縁に水K1m醪性0グリチルリチン又はそのモノ塩
を原料として常温においてグリチルリチン浴液を#14
#することは、なかなか補単にはゆかない・通常グリデ
ルリチンの使用濃[(0,1〜2.0113の水と遍正
倉のアルカリ中、和剤とを用いて攪拌加熱し、之に等張
化剤を添加するととになる。グリチルリチンとアルカリ
との反応は、温時又は高111[の場合、特Kga&制
のアルカリが接触した場合、値斂に混有する7ラボノイ
ド色本のため着色することがあるので細心の注意が費求
される。現在グリチルリチン溶液の原料となるものは純
度のl&いグリチルリチン及びそのモノ塩(アンモニウ
ム、ナトリウム、カリウム)で6って、&’TI性ジア
ルカリ塩、トリアルカリ塩は製造時のアルカIJ M通
のため着色せるのが多いので医薬用としては用いら1な
い・又グリチルリチン#獣に、特に熱に不安定な例えば
グルクロン酸、アスコルビ7敞或いはシスティンの様な
県智を妃会する場合は、−心の注意を払わねばM時的に
一沈IIl釘出、着色O堝象がおきるおそれがある。
発@省らは、これらの一点を除くため上記の変j[4I
:伴う傾向がある加熱打機を避け、−切富温下でグリチ
ルリチン溶液を簡易に量産化しつる方法として、極め【
有利であるところの主薬の溶解安定剤について榊究を重
ねた。その結果グリチルリチン又はその塩の浴解剤とし
ては尿素及び安息香績ナトリウムが蟻も適切であること
がわかった◎
即ちこれらの醪解剤の鳥一度の浴液な作り、之KIHI
性のグリチルリチ/又はその塩な加えると常温で容易#
IC1!解して、一定の酸性浴液が得られる。次いで適
正なるpu#1整削にてアルカリ曽にならぬ様にp麗を
6〜7に1lllliL、必費に応じて所定のグリチル
リチ/の濃度(0,1−2,0囁)に水に【希釈すれば
本−Jll法の目的を連成することができる。
籍にこの一浴解剤Fi後述する即く、遍にの員良の菫な
V!用することによって(尿素l〜3慢)安息香績ナト
リウム1〜3−】グリチルリチン浴液の等優性が得られ
るので1%に咎汝化剤を制卸する必賛がない。しかもこ
の両濤解剤は生体Kmめて安全であり、医薬品の添加剤
としてのそのlff1Itが大きい◎
次に尿素及び安息香酸す) IJウムのグリチルリチン
化合物に対する溶解能(大約)を表記すると次の如し。
尿IA齢液の主薬クリチルリチンに対する溶解総な^め
る・−ためKに尿素の績度をこくすることが必責である
。j1相浴液に近い50−と33.3−との浴M馳は上
表の通、り大きな差がある。33.3−以下の@[)4
のでは本流の目的には不迩尚である〇−万安息査酸す)
IJクム水溶液の舒解馳は尿素と同じ様な傾向がある
が、尿素にみられるような畿度の差に大きな影響はない
、グリチルリチンな除けば低I11度のものも一解剤と
し″′C便用出来る◎本発&j1は上記の如き確社にも
とすきグリチルリチン又はその塩を醍解するのく一切加
熱逃埋を行わず、常1ilLにおい′CN用なるグリチ
ルリチン浴液を一袈する工巣的−法を一供しようとする
ものである。
この目的を適するためK11lじた本発明の嶽旨とする
ところは%特許請求の範囲に示す即く、グリチルリチン
又はその塩を常温におい【尿素又は安AI酸ナトリ9ム
の如き溶解剤の水浴液に播解し1ここに磯厚なる主薬の
酸性溶液t4、次にpnR1i剤にて円滑KPMb、0
〜7.0となし、之を所定の濃酸に希釈することな籍倣
とするものでめる。なはp剋関葺剤としては通電炭酸ア
ルカリ、炭酸水嵩アルカリ、水酸化アルカリ、クエン酸
ナトリウム。
リン酸二ナトリクム、安息舎酸ナトリウム及びそれらの
水浴液が用いられる。
次に本流について具体的にl11!明する◎〜 尿素を
用いる方法 〜
1jJlilf1 [1)に示す如く漱嵩151’に水
150mK溶解すると殆ど飽和#I液で、sopw囁2
64吋となる。前記の表からみてグリチルリチン2(1
はよ〈浴けて、先ずグリチルリチンの酸性尿素溶液とな
る。PMは約3.4である。之にpIillil整剤と
して1筆削酸化ナトリウム液を徐々に加えてpH6,5
前後とする。こ九によってグリチルリチンとアルカリ剤
との直接加温中和による生薬の変質を防止することがで
きる。次いで水にて希釈して11とすれは216.1t
LJとすれは0.2慢グリチルリチンII液が得らる。
原料をグリチルリチンモノアンモニウム塩を使用する場
合は、実施例〔1〕の如くグリチルリチンの約1.02
債量のアン七ニクム塩を用いる。父グリチルリチンモノ
カリウム塩な使用する場合、夾施劉〔厘)の如くグリチ
ルリチンの約1.046倍菫0カリウム塩を用いる0実
tIfA例[i]、 を厘〕の如く夫々尿素の飽和−献
に溶解し、常温において曖厚なる敏a浴淑となし、両省
の場合はアンモニア試液。
後省はIM水水化化カリウム液てpklを調真し、pH
約6.5となし、これらを水にて希釈して0.2i0.
5囁グリチルリチア114?1iが倚らる0−安息香酸
す) IJウムを用いる方法〜グリチルリチア20tを
原料とし、0.2−グリチルリチン浴液10J’!’j
amする場合、実施例(n)に示す如く、グリチルリチ
ン2(lを4oJy*安息薔域す) I)ラム溶成37
5 wa4に溶解する〇−表mlした如く、v易に溶解
してグリチルリチ/の安息香酸プ゛トリウム浴液が得ら
れる。この場合その液性は溶解剤の敵性によって調整さ
れてPi!5.4となる。次いで、1M*歇化ナトリウ
ム液でpH7に6.5 m恢に一筆し水にて希釈して1
01とすれば0.2暢グリチルリチン溶敵が傭らる。久
にクリチルリチンモノナトリウムな原料として0.21
!クリナルリチンm欣10JをIiI緘する場合は、実
施例EV)に示す如くクリチルリチンの1.L)26倍
のクリチルリチンモノナトリウム20.5#な用い40
)’v 9に女息舎緻ナトリウム液550呵に柵房する
と置鴫なる弱酸性液(pH5,8)な得る。之を上記と
同様に1ii水敏化す) IJクム敵にてpmを約6.
5@後に!li1螢し、水に【希釈いOkとすれば約p
H6,6の0.2’$グリチルリチン溶液が得られる。
次に実施例によって得られた各棟グリチルリチン瀝淑の
主薬、S解蘂の各毅膨及びそれら溶液の生理食塩液に対
する浸透圧比を示すと以下の様である0
実施例(i) Q−2慢グリチルリチン、1.5嚢尿素
・・・・・・・・・浸透圧比0.73m実施例[i)
0.2憾グリチルリチン、2−尿素・・・・・・浸透圧
比LO4s実施例〔厘〕υ、5優グリチルリチン、2q
II尿嵩−・・・・・浸透圧比1刀5;実施例(ff)
0.2惨グリチルリチン、1.5憾安息査鍼ナトリ°
ウム・・・−・浸透圧比・・・・−・0.64a実施例
(V)0.2囁グリ゛チ・ルリチン、 2.2 s安息
香酸ナト1ノウム・・・・・・&透圧比1.08u
使用されるグリチルリチンの磯震が(3,1−2,01
1の一せ、浴Ps桑〇−直は上記以外の広範囲の一度が
とられる。夾′l#A?41C■〕〔■〕〔V〕の様な
浴液が調製された場合、その生理食塩液に対′する一&
透圧比は1.0強となり、港解剤が等張化剤0−きをな
し、等張化のため%に仙の条剤な添加する公費がない・
・本床によって侍らる\効果な述べると次の様である。
グリチルリチン又はその塩を冨謳でiI6ali1wt
に仕込む畢が出来る事は、小規模で製品のItIIIL
化がb」能となり、工業的方法として1゛判であると同
時に加熱行程が雀かれるので品質の損失がなく、−品の
均一性が保たれる。殊に熱に弱い他の薬−を配合せんと
する場&M利である。本床によって#I解幼釆をもたら
す尿素又は安息香険ナトリウムは溶解剤として役立つの
みならず等張化剤としての幼果があり、製品の安全性が
一保出米る〇実施例(1)
尿素15(lを水150呪に浴解し、これに常温におi
てグリチルリチン205Ft’少し苑加えると。
暫時にしてa明なさりさらしたば性溶欣(1)H3,4
)が得られる。 区いでIM*tR化す) IJウム敵
約70 wbt 4を徐々に加えmP”t’6.5前後
とし、之な水にて希釈し10壜にすれはQ、2嚢グリナ
ルリチン陪獣(1)Mt8)が倚られる。
実施ガ[uJ
尿素200jFを水200崎に浴解し、グリチルリチン
モノナトリウム20.1を′唐温において徐々に加える
と澄明なる酸性tn欣(PH4,23を得る。
次いでアンモニア試g、を注意深く添加してPHを6.
51iJ41tとし、これを水にて希釈し11とすれば
2S溶液、さらにlO〕にすれば0.2僑グリチルリチ
ア浴i[(’Dki 6,83 km ル。
実施例〔厘〕
尿素160ft’水160崎に緩解し、これに常温にお
いてクリチルリンモノカリ9ム41.8ff4を修々に
加えると暫時にしてfjt鴫なさらざらした識性醪衣(
pH’4.5)が優られる。′ 久いで1m水酸化カリ
ウム液約90呵な注を鑵〈加え、Pklk’6.5前後
とし、之な水にて希釈して8I3とすればpHす、8の
0.51!/!Jfルリテン滴敵が侍られる。
実施例(y)
40 W/y %女息膏除ナトリウムm数375呪をと
、す、之にグリチルリチン20ft徐々に加えると智時
にして澄明なは性浴液(pH5,43となる。之にI
M 2に#を化ナトリウム液約50wIm4ヲ*m L
p’klヲ6S前俊となし、次いで水にて#i釈しI
OAとすれば0.2囁グリチルリチン溶液(1)H6,
63が侍られる。
実施ガ〔マ〕
40 Vv囁安息香除ナトリウム−液550吋をとり、
これに常温にてグリチルリチンモノナトリウム20.5
tを加えると暫時にしてd[な績性帽帥H5,8)とな
る。次いでIM水歇化ナトリクム猷約46吋を添加し、
Pi16.5藺後とし、水にて希釈して1゜Jにすれば
0.2(グリチルリチン嬉取(PM&Ji)が傅らる。[It has been highly praised. Recently, it has been demonstrated at home and abroad that it has a remarkable medicinal effect in improving liver function in chronic hepatitis diseases, and it has also been used as a 1# promoter of r-interferon. Therefore, there is an increasing demand today to reduce the amount of glycyrrhizin, which is stable. ζ- Let us briefly discuss the hierarchy of glycyrrhizin and its salts. Glycyrrhizin (Glycyrrhizin #l) is the diglucuron al of glycyrrhizin! 1, which is a tribasic acid, has a high melting point and is soluble in dilute ethanol and ether, and is castable even in water. The monosalt of glycyrrhizin, like glycyrrhetinth, exhibits a corrugated appearance, and its surface exhibits an agar-like appearance in water, and it dissolves at room temperature, but the monosalt precipitates in a gel-like form as the volume decreases by 1ml. . However, Ji and TriaK
Then, the water becomes KQT-114. Glycyrrhidene #i decomposes into glycyrrhetinic acid and glucuronide by acid decomposition, and turns yellow when heated with alkali. Add a glycyrrhizin bath solution #14 to the edge of the container at room temperature using 1 m water and 0 glycyrrhizin or its monosalt as a raw material.
# It is difficult to compensate for this.Usually, Gliderritin is used at a concentration of 0.1~2.0113 in water and Henshokura's alkaline solution, stirred and heated, and made isotonic. The reaction between glycyrrhizin and alkali occurs when alkali is added at high temperature or at high temperature. Currently, the raw materials for glycyrrhizin solutions are high purity glycyrrhizin and its mono salts (ammonium, sodium, potassium)6, Alkaline salts are not used medicinally because they are often colored due to the alkali IJM used during production.Also, glycyrrhizin is particularly sensitive to heat, such as glucuronic acid, ascorbyl, or cysteine. If you wish to meet a prefectural wisdom, you must be careful, or you may end up with a sudden sinking or coloring. Change j[4I
:Avoiding the heating process that tends to occur, this method is extremely effective for easily mass-producing glycyrrhizin solution at -Kiritomi temperature.
Sakaki conducted extensive research on the advantageous solubility stabilizer for the main drug. As a result, it was found that urea and sodium benzoate were suitable as bath dissolving agents for glycyrrhizin or its salts◎ In other words, these dissolving agents were used to make a bath solution for KIHI.
Glycyrrhiza/or its salt can be easily added at room temperature.
IC1! As a result, a certain acidic bath solution is obtained. Next, in proper pu #1 grinding, add 1 llliL of pu to 6 to 7 to avoid becoming alkaline, and add water to the specified glycyrrhizic concentration (0,1-2,0 whisper) depending on the cost. [If diluted, the purpose of this Jll method can be coupled. In the book, this one-bath detoxifying agent Fi will be described later, and the violet V of the ubiquitous member! By using (urea 1-3) sodium benzoate 1-3-] glycyrrhizin, equidominance of the bath solution can be obtained, so there is no need to limit the concentration of the additive to 1%. What's more, this ammolytic agent is safe for living organisms, and its lff1It as an excipient for pharmaceuticals is large.Next, the solubility of IJum for glycyrrhizin compounds (approximately) is expressed as follows: Like. It is imperative to carefully monitor the performance of urea in order to reduce the total dissolution of urine IA fluid into the main drug, clityrrhizin. As shown in the table above, there is a large difference between the baths of 50- and 33.3-, which are close to the j1 phase bath liquid. 33.3 - Below @[)4
Therefore, it is unethical for the purpose of the mainstream.
The IJ Kum aqueous solution has a tendency to loosen in the same way as urea, but it does not have a big effect on the difference in firmness as seen with urea.Excluding glycyrrhizin, low I11 degrees can also be used as a fixing agent.'' ◎ This product & j1 is suitable for the above-mentioned establishments.To dissolve glycyrrhizin or its salt, no heating or evaporation is performed, and always use 1 liter of glycyrrhizin bath solution for CN use. The purpose of the present invention, which has been modified to suit this purpose, is to provide glycyrrhizin or a salt thereof at room temperature. Dissolve in a water bath solution of a solubilizing agent such as urea or sodium acetate, 1 then add an acidic solution of the main drug, t4, and then lubricate with pnR1i agent KPMb, 0.
~7.0, and dilute it with the specified concentrated acid to imitate it. The roofing agents include electrified alkali carbonate, alkali carbonate, alkali hydroxide, and sodium citrate. Disodium phosphate, sodium benzate and their water bath solutions are used. Next, we will discuss the main stream specifically l11! Clarify ◎ ~ Method using urea ~ 1jJlilf1 As shown in [1], when 150 mK of water is dissolved in sop volume 151', it becomes almost saturated #I liquid, and sopw whisper 2
It will be 64 inches. From the table above, glycyrrhizin 2 (1
Yes, after taking a bath, it first becomes an acidic urea solution of glycyrrhizin. PM is approximately 3.4. Gradually add one drop of sodium oxide solution as a pH adjustment agent to adjust the pH to 6.5.
Before and after. This makes it possible to prevent deterioration of crude drugs due to direct heating neutralization of glycyrrhizin and alkaline agents. Then diluted with water to give 11 and 216.1t.
LJ and 0.2% glycyrrhizin II solution are obtained. When using glycyrrhizin monoammonium salt as the raw material, approximately 1.02% of glycyrrhizin is used as in Example [1].
Use a certain amount of salt. When the monopotassium salt of glycyrrhizin is used, the monopotassium salt of glycyrrhizin is about 1.046 times as strong as the potassium salt of glycyrrhizin, as shown in Example [i], and the saturated solution of urea is used as shown in [I]. It dissolves in water and forms a vaguely sensitive aqueous solution at room temperature. Later, prepare the pkl using IM water potassium hydrate solution and adjust the pH.
6.5 and diluted with water to make 0.2i0.
5 whispers Glycyrrhizia 114?1i is absorbed in 0-benzoic acid) Method using IJum ~ Using 20t of glycyrrhizia as raw material, 0.2-glycyrrhizin bath solution 10J'! 'j
In the case of am, as shown in Example (n), glycyrrhizin 2 (l is 4 oJy * rest) I) Lamb elution 37
5 Dissolves in wa4 〇-ml As shown in the table, it is easily dissolved to obtain a sodium benzoate bath solution of glycyrrhizic acid. In this case, the liquid properties are adjusted depending on the hostility of the solubilizer and Pi! It becomes 5.4. Next, adjust the pH to 7 with 1M* sodium hydroxide solution once every 6.5 m, dilute with water, and add 1
If you set it to 01, you will have a 0.2% glycyrrhizin soluble enemy. 0.21 as a raw material for clityrrhizin monosodium for a long time
! When 10J of clinaluritin m is used as IIII, 1. L) 26x clityrrhizin monosodium 20.5# use 40
)'v 9. Add 550 liters of concentrated sodium solution to the cellar to obtain a weakly acidic solution (pH 5.8). 1ii Water Sensitivity in the same way as above) pm with IJ Kumu enemy to about 6.
5 @ later! Li1 fireflies and water [about p if diluting is OK]
A 0.2'$ glycyrrhizin solution of H6,6 is obtained. Next, the osmotic pressure ratio of each of the main ingredients of the glycyrrhizin extract obtained in the example, each of the S dispersions, and their solutions to physiological saline is as follows.Example (i) Q-2 Chronic glycyrrhizin, 1.5 cyst urea...Osmolality ratio 0.73m Example [i)
0.2-glycyrrhizin, 2-urea...Osmotic pressure ratio LO4s example [厘]υ, 5-dominant glycyrrhizin, 2q
II Urinary volume...Osmotic pressure ratio 1 to 5; Example (ff)
0.2 Glycyrrhizin, 1.5 Glycyrrhizin
Um...-Osmolar pressure ratio...-0.64a Example (V) 0.2 s Gritti Luritin, 2.2 s Sodium benzoate 1 Noum...& Osmolality ratio 1.08u Isoshin of glycyrrhizin used (3,1-2,01
1, a wide range of baths other than the above are taken once.夾′l#A? 41C ■] [■] [V] When a bath solution such as
The osmotic pressure ratio is over 1.0, and the port decomposition agent is not an isotonic agent.
・The effect of being attended to by the main bed is as follows. iI6ali1wt with glycyrrhizin or its salt
It is possible to make a small batch of products in a small scale.
As an industrial method, the heating process is reduced, so there is no loss of quality, and the uniformity of the product is maintained. This is especially useful when combining other drugs that are sensitive to heat. The urea or sodium benzoate that causes #I dissolution by this bed not only serves as a solubilizing agent but also as an isotonic agent, ensuring product safety.Example (1) Dissolve 15 liters of urea in 150 liters of water and add to this at room temperature.
Add a little glycyrrhizin 205Ft'. After a while, it became clear and exposed (1) H3, 4
) is obtained. Gradually add about 70 wbt 4 to make mP't' around 6.5, dilute it with water, make 10 bottles, add 2 capsules of Grinaritin (1) In practice, 200jF of urea is dissolved in 200ml of water, and 20.1ml of glycyrrhizin monosodium is gradually added at a temperature in the troughs to obtain a clear acidic solution (PH 4.23).Next, ammonia Carefully add a sample to bring the pH to 6.
51iJ41t, diluted with water to make 11, then 2S solution, further 1O] to make 0.2glycyrrhizia bathi [('Dki 6,83 km Le. Example [厘] Urea 160 ft' Water 160 It melts in the liquid, and when you add 41.8 ff4 of Krychirurin Monokali 9M to it at room temperature, it becomes fjt's silky, smooth taste (
pH'4.5) is superior. ' Add about 90 liters of 1m potassium hydroxide solution to make Pklk' around 6.5, dilute with water to make 8I3, then the pH will be 0.51 of 8! /! Jf Ruriten's enemy is served. Example (y) When 40 W/y% sodium chloride solution (m number 375) was removed, 20 ft of glycyrrhizin was gradually added to the solution, and a clear bath liquid (pH 5.43) was obtained. to I
Add # to M2 and add sodium solution approximately 50wIm4 *m L
p'klwo 6S Maetoshi and then #i diversion with water I
If OA is 0.2 whisper glycyrrhizin solution (1) H6,
63 will be attended. To carry out, take 550 inches of 40 Vv benzoin de-sodium solution,
Add this to glycyrrhizin monosodium 20.5 at room temperature.
When t is added, d becomes d [Nataru H5, 8). Then about 46 inches of IM water hydroxide was added,
If Pi16.5 is used and diluted with water to 1°J, 0.2 (glycyrrhizin (PM&Ji)) will be obtained.
Claims (1)
において尿嵩又#i女息香酸ナトリウム及びPBmll
剤を作用させることな豐愼とする有用なるグリチルリチ
ン溶[)111116・(2)酸素の磯厚−液にグリチ
ルリチン又はその塩を常温において溶解し%得らるる波
性−厚浴液をp11ilIIllI11剤にて約中性溶
液とし、所定の貴Jlに水にて希釈することを特徴とす
る時針−求の範囲一(1)項記載の有用なるグリチルリ
チンll!1′ftLの一劇法、1 (3)安息香酸す)IJウムの績厚溶液にグリチルリチ
ン又はその塩な常温において111解し、祷らるる絃性
績犀−液をpfi−筆削にて約中性溶液とし1所定O績
kK*にて希釈することを%値とするl1lled求の
範mtii、<1)項記載の有用なるグリナルリチン溶
液の一表法。[Scope of Claims] (1) Glycyrrhizin or its salt, an active ingredient of Glycyrrhiza M, contains urine bulk or #i sodium zoate and PBmll at room temperature.
A useful glycyrrhizin solution [111116] (2) Glycyrrhizin or its salt is dissolved in an oxygen bath solution at room temperature, and the resulting wave-rich bath liquid is used as a p11ilIIIllll11 agent. The useful glycyrrhizin described in item 1 (1) of the hour hand-required range is characterized in that it is made into an approximately neutral solution and diluted with water to a predetermined amount! 1'ftL method, 1 (3) Add glycyrrhizin or its salt to a thick solution of benzoic acid, add glycyrrhizin or its salt at room temperature, and apply the liquid using a PFI brush. A list of useful glinalritin solutions as described in item 1), where the % value is an approximately neutral solution and dilution at a given amount of kK*.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14660281A JPS5849310A (en) | 1981-09-17 | 1981-09-17 | Preparation of useful glycyrrhizin solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14660281A JPS5849310A (en) | 1981-09-17 | 1981-09-17 | Preparation of useful glycyrrhizin solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5849310A true JPS5849310A (en) | 1983-03-23 |
JPS6259118B2 JPS6259118B2 (en) | 1987-12-09 |
Family
ID=15411430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14660281A Granted JPS5849310A (en) | 1981-09-17 | 1981-09-17 | Preparation of useful glycyrrhizin solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5849310A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2616800A1 (en) * | 1987-06-16 | 1988-12-23 | Pernod Ricard | PRODUCTION OF BGLUCURONIDASE ENZYME, GLYCYRRHIZINE HYDROLYSIS AND 18-B-GLYCYRRHETINIC ACID PRODUCTION |
US20060160754A1 (en) * | 2003-08-12 | 2006-07-20 | Nippon Zoki Pharmaceutical Co. Ltd. | Glycyrrhizin high-concentration preparation |
CN104072572A (en) * | 2014-07-21 | 2014-10-01 | 江苏天晟药业有限公司 | Glycyrrhetinic acid sodium and preparation method thereof |
-
1981
- 1981-09-17 JP JP14660281A patent/JPS5849310A/en active Granted
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2616800A1 (en) * | 1987-06-16 | 1988-12-23 | Pernod Ricard | PRODUCTION OF BGLUCURONIDASE ENZYME, GLYCYRRHIZINE HYDROLYSIS AND 18-B-GLYCYRRHETINIC ACID PRODUCTION |
US20060160754A1 (en) * | 2003-08-12 | 2006-07-20 | Nippon Zoki Pharmaceutical Co. Ltd. | Glycyrrhizin high-concentration preparation |
CN104072572A (en) * | 2014-07-21 | 2014-10-01 | 江苏天晟药业有限公司 | Glycyrrhetinic acid sodium and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JPS6259118B2 (en) | 1987-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS62123116A (en) | Aqueous solution agent | |
JPS63177133A (en) | Powder packed developer and manufacture thereof | |
CA2285004C (en) | Stable glycerin iodine concentrate compositions | |
US6153229A (en) | Stable glycerine iodine concentrate compositions | |
GB1171509A (en) | Pyridine Derivatives | |
US2150140A (en) | Derivatives of ascorbic acid having an antiscorbutic action and process for the manufacture of same | |
EP1465663B1 (en) | Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent | |
CN108530382A (en) | A kind of Febuxostat ligustrazine eutectic and its preparation method and application | |
JPS5849310A (en) | Preparation of useful glycyrrhizin solution | |
JPS57134482A (en) | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation | |
US2256604A (en) | Stable aqueous solution of 9-polyhydroxyalkyl-isoalloxazines | |
Flippin et al. | Sulfapyridine and sulfathiazole therapy in pneumococcic pneumonia | |
US2033921A (en) | Solution of ergot alkaloids | |
US2388261A (en) | Riboflavin solution | |
US2389582A (en) | Compounds of 2-sulphanilamido-5-carboxythiazole with vasoconstrictors and their solutions | |
Hanrahan et al. | Additional Studies of the Properties of Taka Amylase1 | |
US2480517A (en) | Fused riboflavin-amide | |
Bauer | Organic compounds in chemotherapy. II. The preparation of formaldehyde sulfoxylate derivatives of sulfanilamide and of amino compounds | |
US2080517A (en) | Medicinal preparations including aminopyridine salts and methods of preparing and utilizing the same | |
US2397903A (en) | Methylene-bis-2 hydroxy-3 naphthoates | |
US2140461A (en) | Cyclohexylammonium mandelate | |
US1582940A (en) | Silver-protein preparation | |
JPS6230794A (en) | Production of concentrated aqueous solution of glycyrrhizin | |
JPH0127060B2 (en) | ||
US2440050A (en) | Riboflavin solution |